TrilliumBiO and T-NeuroDx Announce Strategic Collaboration to Commercialize Blood-Based Biomarkers for Alzheimer's Disease

Partnership aims to accelerate the validation and commercialization of non-invasive diagnostic tools for earlier and more accessible detection of Alzheimer's disease

ROCKVILLE, Md., July 29, 2025 /PRNewswire/ -- TrilliumBiO, a leader in biomarker discovery and precision diagnostics, today announced a strategic collaboration with T-NeuroDx, a pioneering diagnostics company dedicated to developing innovative solutions for detecting neurodegenerative diseases, to advance the development of blood-based biomarker diagnostics for Alzheimer's disease.

This partnership brings together TrilliumBiO's expertise in diagnostic assay development and clinical validation with T-NeuroDx's deep scientific and clinical understanding of Alzheimer's disease pathology and biomarker discovery. Working together, the companies will co-develop and validate blood-based biomarkers that can support earlier diagnosis—addressing one of the most urgent challenges in neurodegenerative care.

"We are proud to partner with T-NeuroDx to bring more accessible, non-invasive diagnostics to patients and providers," said Laura Vivian, CEO of TrilliumBiO. "By combining our diagnostic development capabilities with their cutting-edge biomarker science, we aim to help shift Alzheimer's detection from late-stage confirmation to early, actionable insight."

Blood-based biomarkers represent a transformative opportunity in Alzheimer's disease. As part of the strategic partnership, the teams will commercialize T-Neuro's technology as a Lab Developed Test (LDT) and incorporate it in the evaluation of promising investigational biomarkers that appear earlier in the disease process, designed to support more timely and accessible diagnosis and disease management.

"This partnership accelerates our core mission to advance the early detection of Alzheimer's disease," said Michael Reed, Ph.D., Chief Development Officer of T-NeuroDx. "TrilliumBiO's commitment to providing cutting-edge diagnostic solutions to underserved communities aligns perfectly with our own and strengthens our combined effort to revolutionize early-stage Alzheimer's care."

The initiative will include clinical studies across diverse populations, with the goal of supporting regulatory submissions and the commercialization of clinically validated blood tests for Alzheimer's disease in the coming years.

About TrilliumBiO

TrilliumBiO is a life sciences company specializing in biomarker discovery and the development and commercialization of novel diagnostic tests in collaboration with healthcare innovators. With a proven track record of translating clinical insights into market-ready solutions, TrilliumBiO delivers validated, physician-guided diagnostics that address complex medical challenges. Backed by strong research partnerships and a commitment to evidence-based development, TrilliumBiO transforms discovery into actionable innovations that inform real-world clinical decisions. More information about TrilliumBiO can be found at TrilliumBiO.com.

About T-NeuroDx

T-NeuroDx is an early-stage diagnostics company at the forefront of neurodegenerative disease research, with a primary focus on Alzheimer's disease. The company is developing a revolutionary diagnostic biomarker that can identify Alzheimer's disease at its earliest stages before other biomarkers are detectable or useful. The technology is based on the detection of dysfunctional T cells, a disease initiating factor that precedes the accumulation of aggregated amyloid beta and tau proteins, the traditional markers of Alzheimer's. By enabling early and accurate diagnosis, T-NeuroDx's innovative biomarker technology has the potential to transform the landscape of Alzheimer's drug development and patient care. More information about T-NeuroDx can be found at www.TNeuroDx.com.

Media Contact:

Lane Edwards
Chief of Staff
[email protected]

TrilliumBiO.com

SOURCE TrilliumBiO